eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

March 12, 2026 4:15 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications.The presentation will focus on NCT's potential role in metabolic health...

Read more

Faron Pharmaceuticals Ltd: Holding(s) in Company

March 12, 2026 10:45 AM

Faron Pharmaceuticals (HEL:FARON) (LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if...

Read more

MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale

March 12, 2026 2:30 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as Chief Executive Officer. Mr. Henderson joins at a pivotal inflection point as the Company invests in scaling its existing commercial presence, focused on accelerating adoption of its FDA-cleared platform in the United States to address the...

Read more

AI Maverick Intel Announces Strategic Right of First Refusal Agreement with HEAL Group

March 11, 2026 1:00 PM

AI Maverick Intel, Inc. ("AIMV" or the "Company") today announced that it has entered into a Right of First Refusal Agreement with HEAL Group Holdings Inc. ("HEAL"), effective February 11, 2026, providing AIMV with the right of first refusal to acquire certain business units or assets of HEAL under specified circumstances.Under the terms of the agreement, if HEAL receives a bona fide offer from a third party to acquire certain assets or business...

Read more

Notice of Annual General Meeting in FluoGuide A/S

March 10, 2026 1:05 PM

FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39 29 64 38 (the "Company" or "FluoGuide"), to be held on25 March 2026 at 3.00 PM (CET)at the Company's premises, Titanhus, Titangade 9-13, meeting room - Herakles, DK-2200 Copenhagen N, Denmark.The agenda for the Annual General Meeting is as follows:1. ELECTION OF CHAIRMAN OF THE MEETING2. REPORT ON THE...

Read more

Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform

March 10, 2026 8:45 AM

Alligator Bioscience (STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering Alligator's proprietary bispecific antibody format. The granted patent provides protection for the structural design of tetravalent bispecific antibodies capable of dual antigen binding.The patent covers a...

Read more

MAX BioPharma and Technomark Life Sciences Announce Investment and Partnership Agreement in Developing Oxysterol-Based Drug Candidate for MASH

March 10, 2026 8:00 AM

Today Technomark Life Sciences (www.technomarkls.com) and MAX BioPharma (www.maxbiopharma.com) announced their collaboration in the development of MAX BioPharma's oxysterol drug candidate, Oxy210, for targeting metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is investing in MAX BioPharma by participating in its $13 million Series A raise to initiate and complete a Phase 1a/1b first-in-human study...

Read more

Microbix's Clot-Buster Drug Project Advances

March 10, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that the contract development and manufacturing organization ("CDMO") engaged by its funding and commercialization partner, Sequel Pharma, LLC ("Sequel"), has modernized production methods for the active ingredient (i.e., "Drug Substance") of Kinlytic® urokinase ("Kinlytic"), a biologic for dissolving blood clots.Sequel is...

Read more

Update to Faron's Financial Calendar and Date of the Annual General Meeting in 2026

March 9, 2026 2:00 PM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company's financial calendar 2026.The Annual General Meeting is now planned to take place on 4 May 2026, instead of 30 March 2026 as previously communicated. Faron's Board of Directors will issue a separate company announcement in due course to formally...

Read more

Nomination Committee for Biovica International AB for the 2026 Annual General Meeting

March 9, 2026 12:12 PM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Nomination Committee prior to the 2026 Annual General Meeting will consist of four members, who shall represent the three shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2025, and the Chairman of the Board. The Nomination Committee then appoints a chairman among its members.In accordance with the...

Read more

Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build

March 9, 2026 8:07 AM

When Coeptis Therapeutics Holdings, Inc. (Nasdaq:COEP) and Z Squared Inc. announced their transformational merger in April 2025, the process ahead was substantial: SEC registration, proxy mailing, fairness opinions, shareholder votes, Nasdaq listing review, and a parallel biotech spin-out to architect simultaneously. As of March 2026, that process is largely complete.TRANSACTION AT A GLANCE $835MCombined transaction valuation (per SEC...

Read more

Vicore Pharma to Present at Upcoming Investor Conferences

March 9, 2026 3:15 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:DNB Carnegie Healthcare ConferenceLocation: Stockholm, SwedenFormat: Presentation and 1×1 meetingsPresentation Date and Time: Thursday, March 12 at 9:10 AM CETParticipant: Mikael Nygård, COO10th Annual Nordic-American...

Read more

Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.

March 9, 2026 2:20 AM

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application No. 19/261,360 entitled "Pharmaceutical Compositions for Treating MCT8 Deficiency". Now that Egetis have paid the issue fee, this Notice of Allowance is expected to result in the issuance of a U.S. patent once...

Read more

Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer

March 9, 2026 12:00 AM

Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs. Lobe is pleased to announce the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani has been working with the...

Read more

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026

March 6, 2026 8:00 AM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 fourth quarter and full year on Tuesday, March 17th, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 fourth quarter and full year results on...

Read more

Biovica Announces Planned CEO Succession; Anders Rylander to Step Down During 2026

March 5, 2026 9:40 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The Board of Directors of Biovica International AB today announces that Chief Executive Officer Anders Rylander has informed the Board of his intention to step down as CEO during 2026, as part of a structured succession process.Anders Rylander will remain in his role to ensure continuity and an orderly handover. The transition is expected to be completed during 2026 and, at the...

Read more

OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum

March 5, 2026 9:30 AM

OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market.The extension provides the...

Read more

Genvor, Inc. Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026

March 5, 2026 8:00 AM

Genvor, Inc. (OTCQB:GNVR) ("Genvor" or the "Company") is pleased to announce that Chief Executive Officer Chad Pawlak will be presenting at the National Investment Banking Association's (NIBA) 152nd Investment Conference in Fort Lauderdale, Florida on March 12, 2026.The presentation will include a corporate update highlighting the Company's recent milestones, technology platform advancements and upcoming growth initiatives. Attendees and...

Read more

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences

March 5, 2026 7:40 AM

Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs.The Company announces that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be in Miami, Florida during the upcoming Jefferies and Leerink...

Read more

Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones

March 5, 2026 2:20 AM

Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the promotion of three internal leaders, strengthening its executive team across clinical development, manufacturing, and business development as the company enters a pivotal stage of growth.Vicore has promoted Bernt van den Blink, MD, PhD, to Chief Medical Officer, succeeding...

Read more